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Available online 17 October 2016Background: Critically ill patients often present with hyperglycemia, regardless of previous history of diabetes
mellitus (DM). Hyperglycemia has been associated with adverse outcome in acute myocardial infarction and
acute heart failure. We investigated the association of admission blood glucose level with the clinical picture
and short-term mortality in cardiogenic shock (CS).
Methods: Consecutively enrolled CS patients were divided into five categories according to plasma glucose level
at the time of enrolment: hypoglycemia (glucose b4.0 mmol/L), normoglycemia (4.0–7.9 mmol/L), mild (8.0–
11.9 mmol/L), moderate (12.0–15.9 mmol/L), and severe (≥16.0 mmol/L) hyperglycemia. Clinical presentation,
biochemistry, and short-term mortality were compared between the groups.
Results: Plasma glucose level of 211 CS patients was recorded. Glucose levels were distributed equally between
normoglycemia (26% of patients), mild (27%), moderate (19%) and severe (25%) hyperglycemia, while hypogly-
cemia (2%) was rare. Severe hyperglycemia was associated with higher blood leukocyte count (17.3 (5.8) E9/L),
higher lactate level (4.4 (3.3–8.4)mmol/L) and lower arterial pH (7.23 (0.14)) comparedwith normoglycemia or
mild to moderate hyperglycemia (p b 0.001 for all). In-hospital mortality was highest among hypoglycemic
(60%) and severely hyperglycemic (56%) patients, comparedwith 22% in normoglycemic group (p b 0.01). Severe
hyperglycemiawas an independent predictor of in-hospitalmortality (OR 3.7, 95% CI 1.19–11.7, p= 0.02), when
adjusted for age, gender, LVEF, lactate, and DM.
Conclusions: Admission blood glucose level has prognostic significance in CS. Mortality is highest among patients
with severe hyperglycemia or hypoglycemia. Severe hyperglycemia is independently associated with high in-
hospital mortality in CS. It is also associated with biomarkers of systemic hypoperfusion and stress response.
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1. Introduction
Critically ill patients often presentwith hyperglycemia, regardless of
previous history of diabetes mellitus (DM) [1]. Hyperglycemia in acute
illness partly reflects the activation of stress response mechanisms
that are essential for survival [2,3]. Hypothalamic–pituitary-adrenal
(HPA) axis and the sympathoadrenal system become activated in
response to severe trauma, hemorrhage, sepsis as well as hypotension
or shock of any cause, resulting in high release of stress mediators
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cardiovascular and immune systems, these stress mediators alter the
carbohydrate metabolism by inducing gluconeogenesis, glycolysis and
insulin resistance [2–5]. This in turn leads to hyperglycemia, a condition
associated with adverse outcome among critically ill patients [5,6]. On
the other hand, it has been argued that hyperglycemia is merely an
indicator of severity of illness and not a harmful phenomenon as such
[2].
Previous studies have shown the association between hyperglyce-
mia and increased mortality in acute coronary syndrome (ACS) and
acute heart failure [7,8]. However, data on the significance of blood
glucose level in cardiogenic shock (CS) are sparse [9,10]. CS is the
most severe form of acute heart failure and the leading cause of death
in ACS, characterized by low cardiac output, hypotension and tissue
hypoperfusion. Mortality rates in CS are as high as 40% to 50% [11]. In
addition to hypoperfusion, there is increasing evidence regarding the
role of neurohormonal activation and systemic inflammatory response
in the development of CS [12].
The aim of this study was to investigate the association of blood
glucose levels with patient characteristics and clinical presentation,
and to assess the prognostic significance of admission blood glucose
level in CS.2. Methods
The CardShock study (NCT01374867 at www.clinicaltrials.gov) is a multicenter,
prospective, observational study conducted between 2010 and 2012. The data were
collected from nine tertiary hospitals in eight countries across Europe. We enrolled
consecutive adult CS patients within 6 h of the detection of the shock, and both ACS and
non-ACS etiologies were included. CS was defined as severe hypotension of acute cardiac
cause (systolic blood pressure b90mmHg despite adequate fluid resuscitation or need for
vasopressor therapy to maintain systolic blood pressure N90 mmHg) and signs of
hypoperfusion (altered mental status, cold periphery, oliguria (diuresis b0.5 ml/kg/h for
previous 6 h) or plasma lactate N2 mmol/L). Patients presenting with on-going hemody-
namically significant cardiac arrhythmia were excluded, as well as patients suffering
from CS after cardiac surgery. The detailed design and main results of the CardShock
study have been published previously [13].
Data on patient characteristics and medical history were collected. Echocardiography
was performed, clinical parameters were evaluated, and blood was drawn at the time of
enrolment. Blood leukocytes, hemoglobin, glucose, sodium, alanine aminotransferase
(ALT), lactate, and arterial pH were analyzed locally. Creatinine, C-reactive protein
(CRP), high-sensitivity troponin T (hsTnT), and N-terminal pro-B-type natriuretic peptide
(NT-proBNP, Roche Diagnostics, Basel, Switzerland) were analyzed centrally from blood
samples stored at −80 °C. Estimated glomerular filtration rate (eGFR) was calculated
from creatinine values using the CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration) equation [14]. The investigation conforms to the principles outlined in
the Declaration of Helsinki and the study was approved by local ethics committees.
For statistical analyses, we divided the study population into five different categories
according to plasma glucose level at the time of enrolment: patients with hypoglycemia
(glucose b4.0 mmol/L), normoglycemia (glucose 4.0–7.9 mmol/L, reference group), and
mild (glucose 8.0–11.9 mmol/L), moderate (glucose 12.0–15.9 mmol/L), or severe
hyperglycemia (glucose ≥16.0 mmol/L). The cut-off level of hypoglycemia and the range
of normoglycemia were set according to a recent, clinically oriented review on glucose
management in critically ill patients [15]. The same plasma glucose range of 3.9 mmol/L
as in normoglycemic group was used to categorize the hyperglycemic patients into
three distinct, clinically relevant groups. We compared the medical history, clinical
presentation, biochemical variables, and short-term (in-hospital and 90-day) mortality
between the five groups. Categorical variables are presented as numbers (n) and percent-
ages (%), continuous variables as means with standard deviations (SD) or medians with
inter-quartile ranges (IQR) for variables with a skewed distribution. Group comparisons
were performed with chi-square test for categorical variables and with analysis of
variances (ANOVA) or Kruskal-Wallis test for continuous variables, as appropriate.
Correlations between two continuous variables were tested by using Spearman's rank
correlation (ρ) due to the skeweddistribution of the variables.We built uni- andmultivar-
iate logistic regression models to investigate the association of various baseline plasma
glucose levels with in-hospital mortality, and normoglycemia was used as reference
glucose level. In addition to glucose level, age, gender, and history of DM, themultivariate
model included admission blood lactate and left ventricular ejection fraction (LVEF) for
their prognostic value in critical illness in general and especially in CS, respectively [13,
16,17]. Results are presented as odds ratios (OR) with 95% confidence intervals (CI).
Kaplan–Meier survival curves were used to illustrate differences in mortality between
the groups. The end-point of interest was 90-day mortality. The threshold p-value for sta-
tistical significance was 0.05. Statistical analyses were performed by SPSS 22.0 statistical
software (IBM Corp., Armonk, NY, USA).3. Results
Plasma glucose level was recorded at the time of enrolment in
211 CS patients. Hypoglycemia occurred in five (2%) patients,
normoglycemia in 55 (26%), mild hyperglycemia in 58 (27%), moder-
ate hyperglycemia in 41 (19%), and severe hyperglycemia in 52
(25%) patients. Medical history and patient characteristics are
shown in Table 1. There were no differences in age or gender be-
tween the groups. In contrast, there was a significant difference in
the prevalence of diabetes mellitus (p b 0.001), hypertension (p =
0.04), and hyperlipidemia (p = 0.002). Severely hyperglycemic
patients were the most likely to have an ACS etiology of CS (p =
0.03). They also had the highest body mass indices (BMI) (p =
0.01) and were the most likely to get intubated (p b 0.001).
The clinical presentation and biochemistry at the time of enrol-
ment are shown in Table 2. There were no differences in systolic
blood pressure, heart rate, LVEF, or presence of infection. In contrast,
blood lactate level was significantly higher and arterial pH lower
among severely hyperglycemic patients compared with patients
with normoglycemia and mild or moderate hyperglycemia
(p b 0.001 for all). Patients with severe hyperglycemia also had the
highest blood leukocyte count (p b 0.001). The hypoglycemic
patients presented with the highest levels of lactate, ALT and NT-
proBNP, and the lowest arterial pH and LVEF, but the differences
were statistically non-significant due to the small number of patients
in this group. No differences in the levels of blood hemoglobin, plas-
ma CRP, hsTnT, or eGFR were observed between the groups. Plasma
glucose had a positive correlation with blood leukocyte count (ρ =
0.33, p b 0.001), lactate (ρ = 0.33, p b 0.001), creatinine (ρ = 0.15,
p = 0.03) and hsTnT (ρ=0.17, p = 0.02), and a negative correlation
with arterial pH (ρ = −0.31, p b 0.001).
Both in-hospital and 90-daymortality differed significantly between
the groups (Table 1). Mortality was highest among hypoglycemic and
severely hyperglycemic patients with in-hospital mortality rates of
60% and 56%, respectively, in contrast to 22% amongnormoglycemic pa-
tients (p = 0.005). The Kaplan–Meier survival curves are shown in
Fig. 1. Mean glucose level of in-hospital survivors was lower than that
of non-survivors (11.6 (SD 6.3) vs. 14.4 (6.9) mmol/L, p = 0.005). In
univariate logistic regression analysis for in-hospital mortality, higher
baseline glucose level as a continuous variable (per 1 mmol/L increase)
was associated with increased mortality (OR 1.06, 95% CI 1.02–1.11,
p = 0.005). When the study population was categorized by the prior
DM status, higher plasma glucose level was associated with adverse
outcome in patients without DM (OR 1.10, 95% CI 1.03–1.16, p =
0.005) but not in patients with diagnosed DM (OR 1.02, 95% CI 0.95–
1.09, p = 0.6). Similarly, there was a significant difference in mean
glucose level among in-hospital survivors and non-survivors without
DM (10.1 (SD 4.5) vs. 12.9 (6.8) mmol/L, p = 0.008), but not among
those with diagnosed DM (16.3 (SD 8.5) vs. 17.4 (6.3) mmol/L, p =
0.6). When the small group of hypoglycemic patients was excluded
from the analysis (due to its distinct pathophysiology), the association
between increasing glucose level and in-hospital mortality was even
accentuated among patients without DM (OR 1.12, 95% CI 1.05–1.19,
p = 0.001), but not among those with diagnosed DM (OR 1.01, 95% CI
0.94–1.09, p = 0.7).
When glucose was considered a categorical variable and
normoglycemia used as reference level, severe hyperglycemia was a
strong predictor of in-hospital mortality (OR 4.5, 95% CI 1.9–10.5,
p b 0.001), whereas mild (OR 1.7, 95% CI 0.75–4.1, p = 0.2) and
moderate hyperglycemia (OR 1.9, 95% CI 0.75–4.6, p = 0.2) were not
significantly associated with higher mortality. Hypoglycemia (OR 5.4,
95% CI 0.80–35.9, p = 0.08) also showed a trend towards increased
mortality. In multivariate logistic regression analysis, severe hypergly-
cemia was independently associated with increased in-hospital
mortality (OR 3.7, 95% CI 1.19–11.7, p = 0.02) after adjusting for age,
gender, plasma lactate, LVEF, and history of DM (Table 3).
Table 1
Patient characteristics, medical history and mortality.
All Hypoglycemia Normoglycemia Mild hyperglycemia Moderate hyperglycemia Severe hyperglycemia p value
N (%) 211 5 (2) 55 (26) 58 (27) 41 (19) 52 (25)
Female 54 (26) 2 (40) 12 (22) 16 (28) 7 (17) 17 (33) 0.40
Age (SD), years 67 (12) 65 (10) 65 (13) 67 (13) 68 (12) 67 (10) 0.82
BMI, kg/m2 26.7 (4.0) 27.0 (3.1) 25.8 (4.5)⁎ 25.9 (4.1)† 27.0 (3.6) 28.3 (3.2)⁎† 0.01
ACS etiology 170 (81) 3 (60) 38 (69) 47 (81) 34 (83) 48 (92) 0.03
PCI 143 (68) 3 (60) 30 (55) 41 (71) 30 (73) 39 (75) 0.16
Resuscitation 59 (28) 1 (20) 13 (24) 11 (19) 14 (34) 20 (38) 0.16
Intubation 131 (64) 2 (40) 24 (44) 38 (67) 24 (60) 43 (86) b0.001
Medical history
Diabetes mellitus 58 (27) 1 (20) 4 (7) 11 (19) 15 (37) 27 (52) b0.001
Hypertension 129 (61) 3 (60) 28 (51) 30 (52) 30 (73) 38 (73) 0.04
Hyperlipidemia 97 (46) 4 (80) 16 (29) 22 (38) 22 (54) 33 (63) 0.002
Coronary artery disease 72 (34) 3 (60) 16 (29) 16 (28) 13 (32) 24 (46) 0.15
Congestive heart failure 35 (17) 0 (0) 6 (11) 10 (17) 6 (15) 13 (25) 0.28
Previous MI 53 (25) 2 (40) 10 (18) 13 (22) 10 (24) 18 (35) 0.32
Asthma/COPD 18 (9) 1 (20) 6 (11) 4 (7) 2 (5) 5 (10) 0.70
Mortality
In-hospital 77 (36) 3 (60) 12 (22) 19 (33) 14 (34) 29 (56) 0.005
90-day 85 (41) 3 (60) 14 (26) 22 (39) 15 (37) 31 (60) 0.008
BMI = body mass index, ACS = acute coronary syndrome, PCI = percutaneous coronary intervention, MI=myocardial infarction, COPD= chronic obstructive pulmonary disease. Cat-
egorical variables are presented as numbers (percentages), continuous variables asmeans (standard deviation) for normally distributed variables. P-values are for the differences between
the groups (⁎ and † indicate, between which two groups).
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In this prospective study of an unselected adult CS population, we
have fourmainfindings. First, blood glucose levels rangewidely fromhy-
poglycemic to highly elevated values in CS. Patients can be clearly cate-
gorized according to their baseline blood glucose level into clinically
relevant groups which have prognostic significance. Second, severe hy-
perglycemia is associated with biomarkers of systemic hypoperfusion
and stress response. Third, both hypoglycemia and severe hyperglycemia
are associated with high mortality in CS, whereas normoglycemia at
presentation suggests a relatively favorable outcome. Prior DM statusTable 2
Clinical presentation and biochemistry at the time of enrolment.
All Hypoglycemia Normoglycemia M
N (%) 211 5 (2) 55 (26) 5
Systolic BP; mmHg (SD) 77 (14) 74 (14) 79 (11) 8
MAP; mmHg 57 (11) 54 (7) 58 (9) 5
HR, beats/min 90 (28) 79 (17) 85 (29) 9
LVEF; % 33 (14) 26 (9) 34 (15) 3
Sinus rhythm, n (%) 154 (74) 3 (60) 43 (80) 4
Infection, n (%) 30 (14) 0 (0) 9 (17) 8
Lactate N2 mmol/L, n (%) 150 (72) 4 (80) 30 (56) 3
Confusion, n (%) 142 (68) 3 (60) 30 (55) 4
Cold periphery, n (%) 199 (95) 5 (100) 51 (94) 5
Oliguria, n (%) 115 (55) 3 (60) 23 (42) 3
Biochemistry
Leukocytes; E9/L 14.4 (5.6) 13.8 (3.6) 11.9 (4.5)⁎ 1
Hemoglobin; g/L 129 (22) 116 (11) 126 (25) 1
eGFR; ml/min/1.73m2 63 (29) 59 (40) 63 (28) 6
Sodium; mmol/L 137 (5) 139 (5) 136 (6) 1
ALT; U/L 62 (29–159) 466 (74–801) 64 (25–158) 4
Glucose; mmol/L 10.7 (7.8–15.8) 3.2 (2.7–3.5) 6.9 (6.2–7.6) 9
Lactate; mmol/L 2.8 (1.7–5.6) 8.3 (2.7–14.0) 1.8 (1.2–3.2)⁎ 2
Arterial pH 7.30 (0.13) 7.19 (0.22) 7.35 (0.12)⁎ 7
NT-proBNP; ng/L 2501 26,300 3759 2
(608–9015) (19,129–33,471) (550–9806) (
hsTnT; ng/L 2120 1052 1717 1
(389–5417) (278–1828) (132–4925) (
CRP; mg/L 15 (4–49) 61 (39–84) 22 (5–83) 9
BP= blood pressure, MAP=mean arterial pressure, HR= heart rate, LVEF = left ventricular
ferase, NT-proBNP=N-terminal prohormone B-type natriuretic peptide, hsTNT = high-sensit
(percentages). Continuous variables are presented asmeans (standard deviation) for normally d
tribution. P-values are for the differences between the groups (⁎, † and ‡ indicate, between whimodifies the prognostic value of admission blood glucose. Finally, severe
hyperglycemia is an independent predictor of in-hospital mortality.
In this CS population, baseline glucose levels were distributed
equally between the groups of normoglycemia as well as mild, moder-
ate, and severe hyperglycemia. Themedical history differed significant-
ly between the groups and the prevalence of DM was highest among
severely hyperglycemic patients and lowest among normoglycemic
patients. High blood glucose levels among diabetic patients may be
related to the excessive hepatic glucose production and peripheral
insulin resistance that are constantly present and even accentuated
during critical illness [1,18].ild hyperglycemia Moderate hyperglycemia Severe hyperglycemia p value
8 (27) 41 (19) 52 (25)
0 (10) 74 (13) 76 (18) 0.19
9 (10) 55 (10) 54 (12) 0.07
5 (24) 92 (31) 89 (31) 0.34
2 (14) 36 (14) 31 (13) 0.43
9 (84) 26 (63) 33 (65) 0.05
(14) 8 (20) 5 (10) 0.56
9 (67) 31 (78) 46 (90) 0.002
1 (73) 27 (68) 41 (79) 0.08
4 (93) 39 (95) 50 (96) 0.94
5 (61) 21 (53) 33 (65) 0.14
4.0 (5.5)† 14.5 (5.1) 17.3 (5.8)⁎† b0.001
29 (22) 130 (23) 131 (18) 0.54
9 (29) 66 (29) 56 (31) 0.30
37 (5) 137 (4) 136 (6) 0.57
7 (30–132) 59 (32–129) 89 (39–207) 0.41
.4 (8.7–10.6) 13.4 (12.7–14.5) 20.8 (18.8–25.2) b0.001
.6 (1.8–4.8)† 2.6 (2.1–4.6)‡ 4.4 (3.3–8.4)⁎†‡ b0.001
.30 (0.11)† 7.31 (0.11)‡ 7.23 (0.14)⁎†‡ b0.001
520 2015 2426 0.33
647–8537) (563–8904) (601–7294)
485 2616 2629 0.40
243–6462) (570–5244) (975–7842)
(4–40) 18 (5–75) 12 (4–35) 0.24
ejection fraction, eGFR = estimated glomerular filtration rate, ALT = alanine aminotrans-
ivity troponin T, CRP = C-reactive protein. Categorical variables are presented as numbers
istributed variables and asmedians (inter-quartile range) for variables with a skewed dis-
ch two groups).
Fig. 1. Kaplan–Meier survival curves.
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Previous studies have shown the association of both mild and severe
hypoglycemia with increased mortality in critically ill patients
[19–21]. In the present study, excessive dose of insulin or some other
DM medication was unlikely the cause of hypoglycemia, since only
one out offive hypoglycemic patients had a diagnosis of DM. Instead, se-
vere acute cardiac failure was especially evident among hypoglycemic
patients, as evidenced by low LVEF and high NT-proBNP levels that
were elevated up to ten-fold compared with other groups. In four out
of five hypoglycemic patients, plasma ALT levels were also markedly
elevated, suggesting hepatic congestion and hepatocyte injury [22,23].
This may partly inhibit the adequate response to stress mediators and
induce hypoglycemia due to insufficient level of hepatic gluconeogene-
sis and glycolysis. Moreover, clearly acidotic pH values and high lactate
levels indicated profound hypoperfusion among these patients. In
addition to hypoperfusion, hepatic dysfunction as such may increase
blood lactate levels, since liver is themajor site of lactate clearance [24].
Acidosis and hyperlactatemia were prevalent not only among hypo-
glycemic patients but also among patients with severe hyperglycemia.
In CS, low cardiac output and hypotension cause both hyperlactatemia
due to insufficient tissue perfusion, and hyperglycemia due to stress re-
sponse and subsequent rise in the concentrations of catecholamines and
cortisol. In this study, plasma glucose levels correlated positively with
lactate levels and negatively with arterial pH levels. In the presence of
systemic hypoperfusion and insufficient oxygen supply, the carbohy-
drate metabolism is shifted towards anaerobic metabolism, resultingTable 3
Multivariate regression analysis for in-hospital mortality.
OR 95% CI p value
Age, per 1 year increase 1.05 1.02–1.09 0.002
Male gender 0.67 0.29–1.5 0.35
Plasma glucose
Hypoglycemia 1.8 0.16–20.0 0.64
Normoglycemia Ref
Mild hyperglycemia 1.5 0.52–4.4 0.45
Moderate hyperglycemia 2.9 0.90–9.1 0.08
Severe hyperglycemia 3.7 1.19–11.7 0.02
LVEF, per % increase 0.95 0.92–0.98 b 0.001
Plasma lactate, per 1 mmol/L increase 1.3 1.18–1.5 b 0.001
History of DM 0.59 0.25–1.4 0.22
OR=odds ratio, CI= confidence interval, LVEF= left ventricular ejection fraction, DM=
diabetes mellitus.in the increase of plasma lactate level. On the other hand, lactate can
then be converted back to glucose trough the Cori cycle in the liver. In
addition, both endogenous and exogenous catecholamines induce
accelerated aerobic glycolysis resulting in elevated lactate levels [25].
The strong endogenous stress response in severely hyperglycemic
patients was also demonstrated by high blood leukocyte count.
Moreover, plasma glucose correlated positively with blood leukocytes.
Leukocytosis has been associated with increased mortality in ST-
elevation acute myocardial infarction [26]. As a part of inflammatory
response, leukocytes are mobilized from the bone marrow by soluble
inflammatory mediators such as cytokines. Tissue necrosis stimulates
the inflammatory response, and in this study plasma glucose also
correlated positively with ACS etiology and hsTnT, a marker of myocyte
necrosis. The use of percutaneous coronary intervention (PCI) for the
treatment of patients with CS has increased considerably during the
last decades [27]. Most patients with ACS underwent PCI also in this
study. Despite the frequent use of PCI, elevated plasma glucose was
common and associated with high mortality, suggesting that the
endogenous stress response is not sufficiently attenuated by early
revascularization alone.
Our study indicates, that the baseline blood glucose level has prog-
nostic significance in CS patients. Both in-hospital and 90-daymortality
were highest among hypoglycemic and severely hyperglycemic
patients. In contrast, the prognosis of normoglycemic patients was
relatively favorable, confirming the J-shape association curve of blood
glucose concentrations and mortality generally detected in critically ill
patients [15,28]. Glucose is an established, inexpensive and routinely
monitored biomarker which therefore possesses broad utility and
applicability as a riskmarker.Many novel biomarkers have been studied
in myocardial infarction and heart failure [29,30]. In CS, data on
angiopoetin-2, FGF-23 and GDF-15 have been published, but so far
these biomarkers have not been incorporated in clinical decision
making [31–33].
Interestingly, normoglycemic patients had only mild abnormalities
in both arterial pH and plasma lactate, suggesting less severe hypoper-
fusion and a lesser stress response compared with other groups. Stress
hyperglycemia has not only been associated with increased mortality
in ACS, but also with an increased risk of developing heart failure or
CS [7]. Thus, hyperglycemia is a warning sign of severely disturbed
homeostasis. Multiple studies have shown the association of increasing
lactate level and poor outcome in the critically ill [16,34,35] and it has
been suggested that the prognostic value of hyperglycemia is modified
by simultaneous hyperlactatemia [36]. Importantly, our study demon-
strates that severe hyperglycemia is independently associated with
increased in-hospital mortality. Highly elevated blood glucose as such
may be harmful due to its influences on serum osmolality and fluid
balance [37]. However, when the study population was dichotomized
according to prior DM history, mean plasma glucose level of non-
survivors was significantly higher among patients without DM, but
not among patients with previous diagnosis of DM. Our results thus
suggest, that the predictive value of plasma glucose on short-term
mortality appliesmainly to non-diabetic patients. In contrast, amongdi-
abetic patients there are multiple factors impacting the plasma glucose
level during acute illness. These include the individual glycemic balance,
the type of DM medication, and especially the pathophysiology of DM
itself: insulin resistance and hepatic overproduction of glucose even in
normal status. Our findings confirm the observations about the role of
prior DM status on the prognostic value of glucose [1,6,10,28,38].
Hence, it has been suggested, that it is the relative rather than the abso-
lute level of hyperglycemia that should be considered during acute ill-
ness [1,28,39].
Our study has certain limitations. First, no data on the DM medica-
tion or use of insulin treatment was available. However, as discussed
above, the predictive value of glucose level is blurred by many factors
in DM patients, and only one fourth of the study population were
diabetics. Furthermore, as blood glucose level in this study was
52 A. Kataja et al. / International Journal of Cardiology 226 (2017) 48–52measured at the time of enrolment, most likely few, if any, patients had
received insulin therapy by the time of blood sampling.
Conclusions
Admission blood glucose level has prognostic significance in
cardiogenic shock. Mortality is highest among hypoglycemic and se-
verely hyperglycemic patients, whereas normoglycemia at presentation
is associated with relatively favorable prognosis. Severe hyperglycemia
is associated with biochemical findings of systemic hypoperfusion and
stress response. Moreover, severe hyperglycemia is an independent
predictor of in-hospital mortality. Hypoglycemic patients present with
findings of profound hypoperfusion and hepatic congestion.
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